Stock 002252 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Shanghai RAAS Blood Products Co., Ltd.

Shanghai RAAS Blood Products Co., Ltd. Stock price

Equities

002252

CNE100000C31

Pharmaceuticals

End-of-day quote Shenzhen Stock Exchange
Other stock markets
 06:00:00 2023-12-07 pm EST 		Intraday chart for Shanghai RAAS Blood Products Co., Ltd. 5-day change 1st Jan Change
8.41 CNY +1.82% +3.06% +32.65%
Nov. 29 Grifols Negotiating Potential Deal to Sell Shanghai RAAS Stake to China Merchants Group MT
Nov. 23 Shanghai RAAS Blood Products Co., Ltd. completed the acquisition of 67.22% stake in Guangxi Guanfeng Biological Products Co., Ltd. from Li Guanfeng, Wei Xianghong and Huang Keliang. CI

Financials

Sales 2023 * 7.85B 1.1B Sales 2024 * 9.1B 1.27B Capitalization 55.89B 7.8B
Net income 2023 * 2.24B 312M Net income 2024 * 2.57B 359M EV / Sales 2023 *
7,12x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 *
6,14x
P/E ratio 2023 *
25,5x
P/E ratio 2024 *
22,1x
Employees 3,121
Yield 2023 *
-
Yield 2024 *
-
Free-Float 65.71%
More Fundamentals * Assessed data

Chart Shanghai RAAS Blood Products Co., Ltd.

Dynamic Chart

Latest news about Shanghai RAAS Blood Products Co., Ltd.

Grifols Negotiating Potential Deal to Sell Shanghai RAAS Stake to China Merchants Group MT
Shanghai RAAS Blood Products Co., Ltd. completed the acquisition of 67.22% stake in Guangxi Guanfeng Biological Products Co., Ltd. from Li Guanfeng, Wei Xianghong and Huang Keliang. CI
Shanghai RAAS Blood Products Co., Ltd. completed the acquisition of 27.77% stake in Guangxi Guanfeng Biological Products Co., Ltd. from Hezhou Anxin Qianneng Phase III Investment Fund Partnership Enterprise (Limited Partnership). CI
Shanghai RAAS Blood Products Co., Ltd. signed an equity acquisition agreement to acquire a 67.22% stake in Guangxi Guanfeng Biological Products Co., Ltd. from Li Guanfeng, Wei Xianghong and Huang Keliang for CNY 340 million CI
Shanghai RAAS Blood Products Co., Ltd. agreed to acquire a 27.77% stake in Guangxi Guanfeng Biological Products Co., Ltd. from Hezhou Anxin Qianneng Phase III Investment Fund Partnership Enterprise (Limited Partnership) CI
Grifols shares soar after 2023 profit outlook upgrade RE
Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Shanghai RAAS Blood Products Co., Ltd.'s Equity Buyback Plan announced on July 7, 2023. CI
Shanghai RAAS Blood Products Co., Ltd.'s Equity Buyback announced on July 7, 2023, has closed with 136,153,070 shares, representing 2.02% for CNY 999.69 million. CI
Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
RAAS Blood Products to Expand Shanghai Factory for 1.6 Billion Yuan MT
Shanghai RAAS Blood Products Co., Ltd. commences an Equity Buyback for CNY 1,000 million worth of its shares, under the authorization approved on July 6, 2023. CI
Grifols Reportedly in Talks to Sell Raas Stake to China Resources CI
ADRs End Higher, Grifols, Victrex Trade Actively DJ
Grifols Shares Rise on Potential Sale of Shanghai RAAS Stock for $1.5 Billion DJ
More news

Press releases Shanghai RAAS Blood Products Co., Ltd.

Shanghai RAAS Blood Products : Grifols and Shanghai RAAS close their strategic alliance in China AQ
More press releases

News in other languages on Shanghai RAAS Blood Products Co., Ltd.

Grifols se dispara en bolsa tras mejorar sus perspectivas para 2023
Grifols : le titre grimpe en vue d'une éventuelle cession
Borse Europa, aumento su speranze di pausa Fed, crolla Entain
El Ibex-35 espera a la Fed en máximos de casi dos meses y Grifols se dispara
Grifols se dispara ante la posible venta de una parte de Shanghai RAAS
More news

Quotes and Performance

1 day+1.82%
1 week+3.06%
Current month+5.79%
1 month+18.79%
3 months+23.49%
6 months+21.18%
Current year+32.65%
More quotes

Highs and lows

1 week
7.99
Extreme 7.99
8.56
1 month
7.02
Extreme 7.02
8.56
Current year
6.03
Extreme 6.03
8.56
1 year
5.59
Extreme 5.59
8.56
3 years
4.98
Extreme 4.98
8.56
5 years
4.98
Extreme 4.98
15.81
10 years
4.98
Extreme 4.98
26.67
More quotes

Managers and Directors - Shanghai RAAS Blood Products Co., Ltd.

Managers TitleAgeSince
Jun Xu CEO
 Chief Executive Officer 59 2011
Wei Bing Hu CHM
 Chairman 59 2003
Hong Qiu IRC
 Investor Relations Contact - -
Members of the board TitleAgeSince
Tomás Dagá Gelabert BRD
 Director/Board Member 67 2020
Yue Wen Zheng BRD
 Director/Board Member 61 2007
David Ian Bell BRD
 Director/Board Member 69 2020
More insiders

ETFs positioned on Shanghai RAAS Blood Products Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
GLOBAL X CHINA BIOTECH INNOVATION ETF - USD ETF Global X China Biotech Innovation ETF - USD
5.14% 2 M€ -15.31% -
VANECK NEW CHINA ESG UCITS ETF - USD ETF VanEck New China ESG UCITS ETF - USD
1.19% 6 M€ -13.92%
More ETFs positioned on Shanghai RAAS Blood Products Co., Ltd.

Quotes

Date Price Change Volume
23-12-08 8.41 +1.82% 84,289,110
23-12-07 8.26 +0.98% 74,309,800
23-12-06 8.18 +0.74% 71,068,060
23-12-05 8.12 0.00% 77,429,970
23-12-04 8.12 -0.49% 77,464,000

End-of-day quote Shenzhen Stock Exchange, December 07, 2023

More quotes

Company Profile

Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin). China accounts for 96.6% of net sales.
Sector
Pharmaceuticals
Calendar
2023-12-11 - Extraordinary Shareholders Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai RAAS Blood Products Co., Ltd.

Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
8.41CNY
Average target price
9.075CNY
Spread / Average Target
+7.91%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. Stock Shanghai RAAS Blood Products Co., Ltd.
+32.65% 7 682 M $
CSL LIMITED Stock CSL Limited
-7.24% 84 876 M $
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-13.64% 38 368 M $
BIOGEN INC. Stock Biogen Inc.
-13.59% 34 648 M $
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
+6.30% 21 053 M $
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-10.19% 17 884 M $
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
-50.96% 16 265 M $
UCB Stock UCB
+4.13% 15 421 M $
INCYTE CORPORATION Stock Incyte Corporation
-31.90% 12 366 M $
GRIFOLS, S.A. Stock Grifols, S.A.
+31.71% 8 867 M $
Biopharmaceuticals
  1. Stock
  2. Equities
  3. Stock Shanghai RAAS Blood Products Co., Ltd. - Shenzhen Stock Exchange
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer